Vesalius Biocapital offers venture capital
to young European innovative life science companies

Friday, June 15, 2012 News

Skyline Diagnostics BV and LabPMM GmbH are proud to announce a new commercial testing service for Acute Myeloid Leukemia (AML) patients in Europe

As of June 15, 2012, a comprehensive molecular diagnostic testing service is available for any hospital in Europe. The assay menu consists of Skyline’s AMLprofilerTM, and LabPMM’s LeukostratTM FLT3 and NPM1 Mutation Testing. The standardized comprehensive assays provide 8 of the most powerful diagnostic markers to perform accurate AML molecular subtyping, necessary to stratify and optimize treatment for each patient.

Samples of patient suspected of AML are collected by courier and shipped to LabPMM’s brand new testing facility in Martinsried, Germany. The results are reported back to the customer within five working days.

Skyline Diagnostics’ CEO Henk Vietor: “We have been commercializing the AML profiler as a diagnostic assay through our commercial network in Europe, which allows doctors to rely on accurate and fast testing of 7 key markers in AML1. By launching this joint centralized testing service we can now also offer the qualities of our product to those labs and hospitals that do not wish to set up molecular testing themselves, with the same benefits: fast and reliable.”

Says Jeffrey Miller, CEO of LabPMM GmbH: “We are excited about this collaboration since it represents the commercial launch of our LeukostratTM FLT3 and NPM1 tests in Europe. While offering it as a testing service, it will be the only licensed and standardized, CE IVD registered testing available for FLT3 in Europe. It is our firm belief that a central standardized approach will facilitate the regulatory process and will have a very a real benefit for drug development, clinical trials, and, most importantly, patient outcome”

Contact information:
Skyline Diagnostics BV